25.3 C
New York
Saturday, June 13, 2026

Tag: function

newssourceFORcompanyinformationcontent1marketreleases

Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

NEW YORK, June 12, 2026 /PRNewswire/ -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, applauds today's decision from the...

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

DELLA Highlights Growing Demand for Room-by-Room Climate Control in Southern California

LOS ANGELES, June 12, 2026 /PRNewswire/ -- Southern California homeowners are facing longer hot seasons, rising utility costs, and evolving lifestyle needs. As a...

David Kruzner Joins Trianz | Concierto as Global Transformation Advisory Services Leader

A 20-year Fortune 2000 transformation advisor with board and C-suite credentials — formerly Global Head of Consulting and Innovation at iGATE/CapGemini and Ernst &...

David Kruzner Joins Trianz | Concierto as Global Transformation Advisory Services Leader

A 20-year Fortune 2000 transformation advisor with board and C-suite credentials — formerly Global Head of Consulting and Innovation at iGATE/CapGemini and Ernst &...

From Mini Series to Ultra Slim: LiTime Expands Its Compact Lithium Power Solutions for Space-Constrained Application

LiTime Expands Its Compact Lithium Power Solutions for Space-Constrained Application with 12V 100Ah Ultra Slim LiFePO4 Bluetooth Self-Heating Battery.

Green Science Alliance Developed Nepetalactol based Natural Insect Repellent for Mosquito, Pest

KAWANISHI-CITY, Japan, June 12, 2026 /PRNewswire/ -- Green Science Alliance (Fuji Pigment Co., Ltd. Group) is the green technology company which focuses in developing...

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Making the Invisible Visible: Microscope Breakthrough Will Open Unprecedented View into Our Cells

Biohub and UC Berkeley show that the laser phase plate, a revolutionary device with a laser 100 million times brighter than the Sun, dramatically...

Let an AI Robot Take a Part-Time Job for You: CamdClaw Opens a New Way to Explore Automated Side Income

CamdClaw, an AI-assisted quantitative trading platform, is introducing a different idea: instead of spending more hours working yourself, users can explore market opportunities with the help of an automated AI trading assistant. 
CamdClaw, an AI-assisted quantitative trading platform, is introducing a different idea: instead of spending more hours working yourself, users can explore market opportunities with the help of an automated AI trading assistant.

Wave Neuroscience Announces FDA Clearance of MeRT® for PTSD

FIRST-EVER FDA-CLEARED PERSONALIZED CLINICAL TREATMENT SYSTEM FOR POST-TRAUMATIC STRESS DISORDER (PTSD) ESTABLISHES A NEW CATEGORY IN PRECISION MENTAL HEALTHCARENEWPORT BEACH, Calif., June 11, 2026...

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFunction

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers